IP Library Granted Patent US 8,858,991
Granted Patent B2
US 8,858,991 · App. 13/354,076 · Granted Oct 14, 2014

Delayed release oral pharmaceutical dosage forms comprising MGBG

Inventors: John McKearn (Saint Louis, MO); Jeremy Blitzer (Sunnyvale, CA)
Assignee: Pathologica LLC
A61K9/2054C07C251/12C07C251/78C07C243/16C07C211/13A61K9/4808A61K9/2846A61K9/5026A61K9/5047
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,858,991
App. No.
13/354,076
Granted
Oct 14, 2014
Kind
B2
Abstract

Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.

Claims (6)

1. A method of treating pain comprising the administration, to a patient in need thereof, a delayed-release oral pharmaceutical dosage form comprising MGBG.

2. The method as recited in claim 1 , wherein said delayed release oral pharmaceutical dosage form is an enterically-coated capsule comprising MGBG.

3. The method as recited in claim 2 , wherein the administration of the enterically-coated capsule comprising MGBG results in a reduction of gastrointestinal side effects when compared to a reference standard that is not enterically coated.

4. The method as recited in claim 3 , wherein said gastrointestinal side effects are chosen from nausea, emesis, diarrhea, abdominal pain, oral mucositis, oral ulceration, pharyngitis, stomatitis, irritation of the gastric mucosa, and gastrointestinal ulceration.

5. The method as recited in claim 4 , wherein said gastrointestinal side effect is emesis.

6. The method as recited in claim 3 , wherein MGBG is administered at a dosage level which would result in dose-limiting side effects if administered as a non-enteric coated dosage form.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2013
From: MCKEARN, JOHN; BLITZER, JEREMY
To: PATHOLOGICA LLC
Reel/Frame 030876/0551 →
Continuity (2)
Provisional Application 61434269 · Jan 19, 2011
Related Publication 20120269891A1 · Oct 25, 2012